Mass-market telehealth scale. Mixed compounded and brand semaglutide options. Pricing toward the low end. One v3.0 pillar met (May 2026 review) — published clinical protocol but limited cohort outcome reporting.
Medical Researcher · Western University of Health Sciences
Medically Reviewed By
Dr. Jonathan Snipes, MD · Kim Callender, NP (FNP-BC)
Last medically reviewed: October 15, 2026 · This page is informational and does not constitute medical advice.
Price check, September 20, 2026 — read on Hims & Hers’ own pages, computed from the open dataset:
Semaglutide · brand oral: $298/mo all-in — $149 medication + $149/month membership (brand product; medication rises by dose) membership stackedrises with dose. Weight-loss page read 2026-09-17: no compounded semaglutide or tirzepatide is offered; brand medication 'From $149/mo†' (Wegovy pill, Ozempic pill, Foundayo pill), 'From $199/mo†' (Wegovy pen, Ozempic), 'From $299/mo†' (Zepbound vial and Zepbound KwikPen), Mounjaro and Zepbound pens '$1,899/mo†'; First-partyhims.com · 2026-09-17
Tirzepatide · brand vial: $448/mo all-in — $299 medication + $149/month membership (brand product; medication rises by dose) membership stackedrises with dose. Weight-loss page read 2026-09-17: no compounded semaglutide or tirzepatide is offered; brand medication 'From $149/mo†' (Wegovy pill, Ozempic pill, Foundayo pill), 'From $199/mo†' (Wegovy pen, Ozempic), 'From $299/mo†' (Zepbound vial and Zepbound KwikPen), Mounjaro and Zepbound pens '$1,899/mo†'; First-partyhims.com · 2026-09-17
For comparison — NexLife’s published prices: tirzepatide $139/mo on the 12-month plan ($169 month to month), semaglutide $119 / $139 — $0 membership, same price at every dose, provider oversight and coaching included (read 2026-09-20). Item by item · verification queue.
Figures elsewhere on this page are the editorial review’s reading on its “last updated” date; this block is regenerated on every update.
Overview
Mass-market telehealth scale. Mixed compounded and brand semaglutide options. Pricing toward the low end. One v3.0 pillar met (May 2026 review) — published clinical protocol but limited cohort outcome reporting.
Hims & Hers met 1 of 6 pillars on the May 2026 review (v3.0 rubric); re-scoring on methodology v4.1 is pending. A single pillar met typically reflects a published clinical protocol but limited disclosure on pharmacy traceability, cohort outcomes, or pricing structure.
Pricing
semaglutide oral $298/mo all-in (brand); tirzepatide vial $448/mo all-in (brand). Verify final pricing directly with the provider before purchasing — prices may change.
Trade-offs to know
May 2026 review (v3.0 rubric): 1 of 6 pillars met; re-scoring on methodology v4.1 is pending.
Verify pricing, pharmacy partners, and clinical protocol directly with Hims & Hers before purchasing.
Brand-name medications are FDA-approved; compounded medications are not.
How to evaluate Hims & Hers
If you're considering Hims & Hers, verify directly: (1) named Medical Director and state licensure, (2) the dispensing pharmacy on every shipment label, (3) whether per-batch CoAs (USP <71>, USP <85>, HPLC potency) are available on request, (4) the full out-of-pocket monthly cost across the titration schedule, (5) the FDA-approval status of any medication you're prescribed.
